"Although we have not seen any serious adverse events in clinical experience with ANA975, the health and safety of patients are our first and overriding concern," said Kleanthis G. Xanthopoulos, Ph.D., Anadys' President and CEO. "Consequently, we are suspending this trial for appropriate reasons of precaution while we gain a greater understanding of this recently obtained information."
The new data preliminarily shows intense immune stimulation in animals as side effect. Anadys and Novartis (its collaborator) are now in the process of evaluating these observations in order to determine their next move.
The two companies believe that ANA975 is an effective immunomodulator and therefore a potentially promising agent for patients infected with hepatitis C virus and can’t wait to continue with the program.
Read the full press release.
Comment Preview